Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03563391
Other study ID # CT17USCBUFG01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 30, 2018
Est. completion date May 30, 2020

Study information

Verified date December 2020
Source Nutricia North America
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a prospective, open-label, multi-site, growth, safety and tolerance study to evaluate a NF (New Formula). A minimum of 45 evaluable infants with confirmed growth failure will be enrolled. Growth failure for 30 infants will be due to congenital heart disease and 15 infants due to other organic or non-organic causes. Study infants (in-patient or living with parents/ caregivers at home) will be fed the NF for a period of up through 16 weeks or until the time the infant subject meets criteria for switching to a lower calorie density formula, relative to baseline in infants with growth failure. Weight, height, head circumference and mid upper arm circumference will be measured regularly throughout the study. NF and other food intake, tolerance and stool diaries will be completed regularly. Serious adverse and adverse events will be monitored throughout the study. Infants will be evaluated, at each study visit, for criteria to switch to a lower calorie density formula. The primary objective is to improve weight-for-age z score relative to baseline. The secondary objectives are to improve weight-for-length, length-for-age, head circumference-for-age, mid upper arm circumference-for-age, weight velocity and length velocity z scores relative to baseline.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date May 30, 2020
Est. primary completion date April 7, 2020
Accepts healthy volunteers No
Gender All
Age group 1 Month to 8 Months
Eligibility Inclusion Criteria: 1. Infants must have attained term gestation (=37 weeks of gestational age) at the time of screening 2. Infants, male or female, aged 1 through 8 months 3. Infants with congenital heart disease or other organic/non-organic cause of growth failure with a weight-for-length z score = -1.0 or weight gain = -2.0 z score based on WHO growth standards. (for weight gain metrics please see Appendix I): Weight gain (g) for boys and girls by age ( -2 z scores for weight velocity). Infants with Down syndrome must have a weight for length z-score =-1.0 z score. Infants with Down syndrome who meet the weight gain criterion (= -2.0 z-score weight gain) and have a weight for length z-score >-1.0 z-score will not be eligible for enrolment. 4. Infants expected to consume (or obtain via tube feeding), on average, 80% of their total energy intake from NF for 16 weeks 5. Infants from families who are willing and able to have anthropometrics taken at the required frequency as well as to comply with all other protocol requirements 6. Written informed consent from the parent/caregiver or legal guardian 7. Parent/caregiver or legal guardian must be able to read, write, and understand English Exclusion Criteria: 1. Infants with known or suspected complex gastrointestinal anomalies or dysfunction, hepatic* or renal* dysfunction, or inherited metabolic disorders, congenital neurological insults, suspected or diagnosed conditions associated with malabsorption (e.g. cystic fibrosis) 2. Infants with known or suspected systemic or congenital infections (e.g. human immunodeficiency virus, HBV, HCV) 3. 3. Infants with known or suspected genetic conditions listed in Appendix VI and/or metabolic conditions known to interfere with growth or body dysmorphology that can interfere with obtaining standard anthropometric measurements (weight, length, head circumference, and mid upper arm circumference), with the exception of infants diagnosed with Down syndrome who may be enrolled in the study 4. Infants with known or suspected cow milk allergy or children who have received cow milk formula for 7 days or less 5. Infants expected to consume on average more than 20% of their energy intake from non-NF sources of nutrition: solids, expressed breast milk and /or parenteral nutrition. 6. Child feeding directly at the breast more than twice per day 7. Infants participating in any other studies involving investigational or marketed products concomitantly or within two weeks prior to the entry into the study. Infants participating in vaccination trials, who are only receiving follow-up blood monitoring, are not excluded. 8. Principal Investigator's uncertainty about the willingness or ability of the parent/caregiver or legal guardian to comply with the protocol requirements 9. Infants whose parent is younger than the legal age of consent 10. Infants born large for gestational age (LGA). LGA: Birth weight > 90th percentile for gestational age (please see chart in Appendix I) 11. Infants born small for gestational age (SGA). SGA: Birth weight < 10th percentile for gestational age (please see chart in Appendix I) * Note: For hepatic dysfunction, a conjugated bilirubin >2.0 mg/dL and for renal dysfunction child should not meet any of the pRIFLE criteria for renal disease (estimated creatinine clearance decreased by 25% by the Schwartz formula or urine output <0.5 mL/kg per hour over the previous 8 or more hours) or has chronic medical renal disease. In most children labs need not be obtained. These criteria only come into play when there is a consideration of liver or renal disease in the individual child.

Study Design


Intervention

Other:
New Infant Formula
New Infant Formula is a specialized, nutritionally complete, nutrient-dense infant formula specifically formulated for infants with growth failure.

Locations

Country Name City State
United States GI Care for Kids Atlanta Georgia
United States East Carolina University Greenville North Carolina
United States Nemours Children's Specialty Care Jacksonville Florida
United States The Medical College of Wisconsin Milwaukee Wisconsin
United States Wake Forest University Baptist Medical Center Winston-Salem North Carolina

Sponsors (6)

Lead Sponsor Collaborator
Nutricia North America East Carolina University, GI Care for Kids, Medical College of Wisconsin, Nemours Children's Clinic, Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Gastrointestinal tolerance 3-day diaries 16 weeks
Other Number of adverse events related to new infant formula (New Formula) Number of adverse events evaluated to be related to new infant formula (New Formula) using Adverse Events Decision Tree criteria Up to 21 weeks starting from date of baseline visit
Primary Change in weight-for-age z-score from baseline weight for age z-score at 16 weeks (or at time of meeting criteria to switch to lower density formula if criteria is met prior to 16 weeks) and z-score at baseline 16 weeks
Secondary Weight-for-length z-score 16 weeks
Secondary Length-for-age z-score 16 weeks
Secondary Head circumference-for-age z-score 16 weeks
Secondary Mid upper arm circumference (MUAC)-for-age z-score 16 weeks
Secondary Weight velocity z-score 16 weeks
Secondary Length velocity z-score 16 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04992793 - Paediatric Brain Injury Following Cardiac Interventions
Recruiting NCT05213598 - Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
Completed NCT04136379 - Comparison of Home and Standard Clinic Monitoring of INR in Patients With CHD
Completed NCT04814888 - 3D Airway Model for Pediatric Patients
Recruiting NCT04920643 - High-exchange ULTrafiltration to Enhance Recovery After Pediatric Cardiac Surgery N/A
Completed NCT05934578 - Lymphatic Function in Patients With Fontan Circulation: Effect of Physical Training N/A
Recruiting NCT06041685 - Effect of Local Warming for Arterial Catheterization in Pediatric Anesthesia N/A
Recruiting NCT05902013 - Video Laryngoscopy Versus Direct Laryngoscopy for Nasotracheal Intubation N/A
Not yet recruiting NCT05687292 - Application of a Clinical Decision Support System to Reduce Mechanical Ventilation Duration After Cardiac Surgery
Not yet recruiting NCT05524324 - Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT N/A
Completed NCT02746029 - Cardiac Murmurs in Children: Predictive Value of Cardiac Markers
Completed NCT03119090 - Fontan Imaging Biomarkers (FIB) Study
Completed NCT02537392 - Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease N/A
Recruiting NCT02258724 - Swiss National Registry of Grown up Congenital Heart Disease Patients
Completed NCT01966237 - Milrinone Pharmacokinetics and Acute Kidney Injury
Terminated NCT02046135 - Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery Phase 2
Recruiting NCT01184404 - Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac Surgery N/A
Completed NCT01548950 - Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension N/A
Completed NCT01821287 - Nutritional Failure in Infants With Single Ventricle Congenital Heart Disease N/A